Daily Med

Current Medication Information

Options

Download the FDA official PDF of this label

RxNorm Names

naphazoline hydrochloride (Naphazoline Hydrochloridesolution/ drops 
[Bausch & Lomb Incorporated]

Drug Label Sections

Description

Naphazoline Hydrochloride Ophthalmic Solution USP, 0.1%, a sterile solution, is an ocular vasoconstrictor and imidazoline derivative sympathomimetic amine. It occurs as a white, odorless, crystalline powder having a bitter taste and is freely soluble in water and in alcohol. The active ingredient is represented by the following structural formula:

Image from Drug Label Content
Image from Drug Label Content
Image from Drug Label Content

Chemical Name: 2-(1-naphthylmethyl)-2-imidazoline monohydrochloride

Each mL Contains: ACTIVE: Naphazoline Hydrochloride, 1 mg (0.1%); INACTIVES: Boric Acid, Sodium Chloride, Edetate Disodium, Sodium Carbonate, Purified Water. Sodium Carbonate and/or Hydrochloric Acid may be added to adjust pH (5.5 - 7.0). PRESERVATIVE ADDED: Benzalkonium Chloride 0.01%.

Clinical Pharmacology

Naphazoline constricts the vascular system of the conjunctiva. It is presumed that this effect is due to direct stimulation action of the drug upon the alpha adrenergic receptors in the arterioles of the conjunctiva resulting in decreased conjunctival congestion. Naphazoline belongs to the imidazoline class of sympathomimetics.

Indications and Usage

Naphazoline Hydrochloride Ophthalmic Solution is indicated for use as a topical ocular vasoconstrictor.

Contraindications

Contraindicated in the presence of an anatomically narrow angle or in narrow angle glaucoma or in persons who have shown hypersensitivity to any component of this preparation.

Warnings

NOT FOR INJECTION INTO THE EYE - FOR TOPICAL USE ONLY.

Patients under therapy with MAO inhibitors may experience a severe hypertensive crisis if given a sympathomimetic drug. Use in pediatric patients, especially infants, may result in CNS depression leading to coma and marked reduction in body temperature.

Precautions

General

Use with caution in the presence of hypertension, cardiovascular abnormalities, hyperglycemia (diabetes), hyperthyroidism, infection or injury.

Information for patients

Patients should be advised to discontinue the drug and consult a physician if relief is not obtained within 48 hours of therapy, if irritation, blurring or redness persists or increases, or if symptoms of systemic absorption occur, i.e., dizziness, headache, nausea, decrease in body temperature, or drowsiness.

To prevent contaminating the dropper tip and solution, do not touch the eyelids or the surrounding area with the dropper tip of the bottle. If solution changes color or becomes cloudy, do not use.

Drug Interactions

Concurrent use of maprotiline or tricyclic antidepressants and naphazoline may potentiate the pressor effect of naphazoline. Patients under therapy with MAO inhibitors may experience a severe hypertensive crisis if given a sympathomimetic drug. (See WARNINGS).

Pregnancy

Category C

 Animal reproduction studies have not been conducted with naphazoline. It is also not known whether naphazoline can cause fetal harm when administered to a pregnant woman or can effect reproduction capacity. Naphazoline should be given to a pregnant woman only if clearly needed.

Nursing mothers

It is not known whether naphazoline is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when naphazoline is administered to a nursing woman.

Pediatric use

Safety and effectiveness in pediatric patients have not been established. See "WARNINGS" and "CONTRAINDICATIONS".

Adverse Reactions

Ocular: Mydriasis, increased redness, irritation, discomfort, blurring, punctate keratitis, lacrimation, increased intraocular pressure.

Systemic: Dizziness, headache, nausea, sweating, nervousness, drowsiness, weakness, hypertension, cardiac irregularities, and hyperglycemia.

Dosage and Administration

Instill one or two drops into the conjunctival sac(s) every three to four hours as needed.

How Supplied

Naphazoline Hydrochloride Ophthalmic Solution USP, 0.1%, is available in a plastic squeeze bottle with controlled drop tip in the following size:

15 mL bottle - Prod. No. 04611

STERILE OPHTHALMIC SOLUTION

Rx only

FOR OPHTHALMIC USE ONLY.

Storage Conditions

Store between 15°- 30°C (59°-86°F).

DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.

KEEP OUT OF REACH OF CHILDREN.

Manufacturing Information

Bausch & Lomb Incorporated

Tampa, FL 33637

©Bausch & Lomb Incorporated

XO50131 (Folded)

XM10028 (Flat)

REV.12/03-62


Naphazoline Hydrochloride (Naphazoline Hydrochloride)
PRODUCT INFO
Product Code24208-725Dosage FormSOLUTION/ DROPS
Route Of AdministrationOPHTHALMICDEA Schedule
INGREDIENTS
Name (Active Moiety)TypeStrength
NAPHAZOLINE HYDROCHLORIDE (NAPHAZOLINE) Active1 MILLIGRAM  In 1 MILLILITER
benzalkonium chlorideInactive 
boric acidInactive 
edetate disodiumInactive 
hydrochloric acidInactive 
waterInactive 
sodium carbonateInactive 
sodium chlorideInactive 
IMPRINT INFORMATION
CharacteristicAppearanceCharacteristicAppearance
ColorScore
ShapeSymbol
Imprint CodeCoating
Size
PACKAGING
#NDCPackage DescriptionMultilevel Packaging
124208-725-061 BOTTLE In 1 CARTONcontains a BOTTLE, DROPPER
115 MILLILITER In 1 BOTTLE, DROPPERThis package is contained within the CARTON (24208-725-06)

Revised: 04/2008Bausch & Lomb Incorporated
Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services